BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bushyhead D, Goldberg D. Use of Hepatitis C-Positive Donor Livers in Liver Transplantation. Curr Hepatol Rep 2017;16:12-7. [PMID: 28243573 DOI: 10.1007/s11901-017-0327-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nangia G, Borges K, Reddy KR. Use of HCV‐infected organs in solid organ transplantation: An ethical challenge but plausible option. J Viral Hepat 2019;26:1362-71. [DOI: 10.1111/jvh.13130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Weinberg EM, Reddy KR. Let's Make a Deal: Shortening the Solid Organ Transplant Waiting Time in Exchange for Transmitting and Treating Hepatitis C Infection in the Era of Safe and Effective Directly Acting Antivirals. Clin Infect Dis 2018;66:293-5. [PMID: 29020223 DOI: 10.1093/cid/cix790] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Curr Opin Organ Transplant 2019;24:351-7. [PMID: 31090648 DOI: 10.1097/MOT.0000000000000651] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sundaram V, Jalan R, Shah P, Singal AK, Patel AA, Wu T, Noureddin M, Mahmud N, Wong RJ. Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality. Hepatology 2021;73:1932-44. [DOI: 10.1002/hep.31566] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Shaffer AA, Thomas AG, Bowring MG, Van Pilsum Rasmussen SE, Cash A, Kucirka LM, Alqahtani SA, Gurakar A, Sulkowski MS, Cameron AM, Segev DL, Durand CM. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. Transpl Infect Dis 2018;20:e12982. [PMID: 30144258 DOI: 10.1111/tid.12982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Kapila N, Khalloufi KA, Flocco G, Menon KVN, Lindenmeyer C, Reino D, Vanatta JM, Ebaid S, Tzakis A, Zervos XB. Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy. J Clin Transl Hepatol 2019;7:122-6. [PMID: 31293911 DOI: 10.14218/JCTH.2019.00014] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Booth IA, Clark JE, LaMattina JC, Barth RN, Haririan A, Ravichandran BR. The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes. J Pharm Pract 2021;:8971900211034261. [PMID: 34289722 DOI: 10.1177/08971900211034261] [Reference Citation Analysis]
8 Bruno S, Nicole B, Nila J D, Gail M, James N, Peter S M, Christopher S H. Heart Transplantation From Hepatitis C-Positive Donors in the Era of Direct Acting Antiviral Therapy: A Comprehensive Literature Review. Transplant Direct 2019;5:e486. [PMID: 31579814 DOI: 10.1097/TXD.0000000000000928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]